T细胞耗竭与呼吸系统疾病关系的研究进展

doi:10.3969/j.issn.1006-5725.2024.13.023

Abstract

Abstract:

T cell exhaustion occurs mostly in chronic infections， cancers and autoimmune diseases. Continuous antigenic stimulation leads to the generation of exhausted T cells， which is characterized by progressive loss of effector function， continuous high expression of inhibitory receptors， transcription and epigenetic changes， and metabolic disorders. The in-depth study of the specific mechanism of T cell exhaustion is providing new ideas for the immunotherapy of chronic infection， lung cancer and chronic airway inflammatory disease in respiratory diseases. This paper discussed the influencing factors and characteristics of T cell exhaustion and reviewed the current research status of T cell exhaustion and respiratory diseases.

Key words: T cell exhaustion, inhibitory receptors, respiratory diseases, immunotherapy

CLC Number:

Ziqi DING,Qian. ZHANG. Research progress in T cell exhaustion and its relationship with respiratory diseases[J]. The Journal of Practical Medicine, 2024, 40(13): 1895-1900.

References 43

1	GALLIMORE A， GLITHERO A， GODKIN A， et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble tetrameric major histocompatibility complex class I-peptide complexes［J］. J Exp Med， 1998，187（9）：1383-1393. doi:10.1084/jem.187.9.1383 doi: 10.1084/jem.187.9.1383
2	SHIN M S， PARK H J， YOUNG J， et al. Implication of IL-7 receptor alpha chain expression by CD8⁺ T cells and its signature in defining biomarkers in aging［J］. Immun Ageing， 2022，19（1）：1-8. doi:10.1186/s12979-022-00324-6 doi: 10.1186/s12979-022-00324-6
3	WHERRY E J. T cell exhaustion［J］. Nat Immunol， 2011， 12（6）：492-499. doi:10.1038/ni.2035 doi: 10.1038/ni.2035
4	LENG A， SHAH M， AHMAD S A， et al. Pathogenesis underlying neurological manifestations of long COVID syndrome and potential therapeutics［J］. Cells， 2023，12（5）：816. doi:10.3390/cells12050816 doi: 10.3390/cells12050816
5	OSUCH S， LASKUS T， PERLEJEWSKI K， et al. CD8⁺ T-cell exhaustion phenotype in chronic hepatitis c virus infection is associated with epitope sequence variation［J］. Front Immunol， 2022，13：903. doi:10.3389/fimmu.2022.832206 doi: 10.3389/fimmu.2022.832206
6	MISHRA K， SINGH M， SARASWAT D， et al. Dysfunctional state of T cells or exhaustion during chronic viral infections and COVID-19： A review［J］. Viral Immunol， 2022，35（4）：284-290. doi:10.1089/vim.2022.0002 doi: 10.1089/vim.2022.0002
7	GAO Z， FENG Y， XU J， et al. T-cell exhaustion in immune-mediated inflammatory diseases： New implications for immunotherapy［J］. Front Immunol， 2022，13：977394. doi:10.3389/fimmu.2022.977394 doi: 10.3389/fimmu.2022.977394
8	DOLINA J S， BRAECKEL-BUDIMIR N V， THOMAS G D， et al. CD8⁺ T cell exhaustion in cancer［J］. Front Immunol， 2021，12：715234. doi:10.3389/fimmu.2021.715234 doi: 10.3389/fimmu.2021.715234
9	BARNOVA M， BOBCAKOVA A， URDOVA V， et al. Inhibitory immune checkpoint molecules and exhaustion of T cells in COVID-19［J］. Physiol Res， 2021，70（S2）：S227-S247.
10	QUIGLEY M， PEREYRA F， NILSSON B， et al.Transcriptional analysis of HIV-specific CD8⁺ T cells shows that PD-1 inhibits T cell function by upregulating BATF［J］. Nat Med，2010，16（10）：1147-1151. doi:10.1038/nm.2232 doi: 10.1038/nm.2232
11	HAN Y， LIU D， LI L. PD-1/PD-L1 pathway： current researches in cancer［J］. Am J Cancer Res， 2020，10（3）：727-742.
12	BROOKS D G， TRIFILO M J， EDELMANN K H， et al. Interleukin-10 determines viral clearance or persistence in vivo［J］. Nat Med， 2006，12（11）：1301-1309. doi:10.1038/nm1492 doi: 10.1038/nm1492
13	HASHIMOTO M， ARAKI K， CARDENAS M A， et al. PD-1 combination therapy with IL-2 modifies CD8⁺ T cell exhaustion program［J］. Nature， 2022，610（7930）：173-181. doi:10.1038/s41586-022-05257-0 doi: 10.1038/s41586-022-05257-0
14	HU Y， HUDSON W H， KISSICK H T， et al. TGF-beta regulates the stem-like state of PD-1⁺ TCF-1⁺ virus-specific CD8 T cells during chronic infection［J］. J Exp Med， 2022，219（10）：e20211574. doi:10.1084/jem.20211574 doi: 10.1084/jem.20211574
15	ELSAESSER H， SAUER K， BROOKS D G. IL-21 is required to control chronic viral infection［J］. Science， 2009， 324（5934）：1569-1572. doi:10.1126/science.1174182 doi: 10.1126/science.1174182
16	CUI C， WANG J， FAGERBERG E， et al. Neoantigen-driven B cell and CD4 T follicular helper cell collaboration promotes anti-tumor CD8 T cell responses［J］. Cell，2021，184（25）：6101-6118. doi:10.1016/j.cell.2021.11.007 doi: 10.1016/j.cell.2021.11.007
17	REN H M， LUKACHER A E， RAHMAN Z S M， et al. New developments implicating IL-21 in autoimmune disease［J］. J Autoimmun，2021，122：102689. doi:10.1016/j.jaut.2021.102689 doi: 10.1016/j.jaut.2021.102689
18	ELAHI S， SHAHBAZ S， HOUSTON S. Selective upregulation of CTLA-4 on CD8⁺ T cells restricted by HLA-B* 35Px renders them to an exhausted phenotype in HIV-1 infection［J］. PLoS Pathog， 2020，16（8）：e1008696. doi:10.1371/journal.ppat.1008696 doi: 10.1371/journal.ppat.1008696
19	OYEWOLE-SAID D， KONDURI V， VAZQUEZ-PEREZ J， et al. Beyond T-cells： functional characterization of CTLA-4 expression in immune and non-immune cell types［J］. Front Immunol， 2020，11：608024. doi:10.3389/fimmu.2020.608024 doi: 10.3389/fimmu.2020.608024
20	CHOCARRO L， BLANCO E， ZUAZO M， et al. Understanding LAG-3 signaling［J］. Int J Mol Sci， 2021，22（10）：5282. doi:10.3390/ijms22105282 doi: 10.3390/ijms22105282
21	HAN J， WAN M， MA Z， et al. The TOX subfamily： all-round players in the immune system［J］. Clin Exp Immunol， 2022，208（3）：268-280. doi:10.1093/cei/uxac037 doi: 10.1093/cei/uxac037
22	SEN D R， KAMINSKI J， BARNITZ R A， et al. The epigenetic landscape of T cell exhaustion［J］. Science， 2016， 354（6316）：1165-1169. doi:10.1126/science.aae0491 doi: 10.1126/science.aae0491
23	刘勋. 结核抗原持续刺激致T细胞耗竭实验研究及亚单位疫苗LT70-DPC的研发［D］. 兰州：兰州大学， 2016.
24	PHILLIPS B L， MEHRA S， AHSAN M H， et al. LAG3 expression in active mycobacterium tuberculosis infections［J］. Am J Pathol， 2015，185（3）：820-833. doi:10.1016/j.ajpath.2014.11.003 doi: 10.1016/j.ajpath.2014.11.003
25	SHEN L， GAO Y， LIU Y， et al. PD-1/PD-L pathway inhibits M.tb-specific CD4⁺ T-cell functions and phagocytosis of macrophages in active tuberculosis［J］. Sci Rep， 2016，6：38362. doi:10.1038/srep38362 doi: 10.1038/srep38362
26	JAYARAMAN P， JACQUES M K， ZHU C， et al. TIM3 mediates T cell exhaustion during mycobacterium tuberculosis infection［J］. PLoS Pathog， 2016，12（3）：e1005490. doi:10.1371/journal.ppat.1005490 doi: 10.1371/journal.ppat.1005490
27	LOMBARDI A， VILLA S， CASTELLI V， et al. T-Cell Exhaustion in Mycobacterium tuberculosis and Nontuberculous Mycobacteria Infection： Pathophysiology and Therapeutic Perspectives［J］. Microorganisms， 2021，9（12）：2460. doi:10.3390/microorganisms9122460 doi: 10.3390/microorganisms9122460
28	LIU X， LI F， NIU H， et al. IL-2 Restores T-Cell Dysfunction Induced by Persistent Mycobacterium tuberculosis Antigen Stimulation［J］. Front Immunol， 2019， 10：2350. doi:10.3389/fimmu.2019.02350 doi: 10.3389/fimmu.2019.02350
29	RHA M S， SHIN E C. Activation or exhaustion of CD8⁺ T cells in patients with COVID-19［J］. Cell Mol Immunol， 2021，18（10）：2325-2333. doi:10.1038/s41423-021-00750-4 doi: 10.1038/s41423-021-00750-4
30	LIU L， WANG A， LIU X， et al. Blocking TIGIT/CD155 signalling reverses CD8⁺ T cell exhaustion and enhances the antitumor activity in cervical cancer［J］. J Transl Med， 2022，20（1）：1-13. doi:10.1186/s12967-022-03480-x doi: 10.1186/s12967-022-03480-x
31	SIEGEL R L， MILLER K D， WAGLE N S， et al. Cancer statistics， 2023［J］. CA Cancer J Clin， 2023，73（1）：17-48. doi:10.3322/caac.21763 doi: 10.3322/caac.21763
32	DUTTA S， GANGULY A， CHATTERJEE K， et al. Targets of immune escape mechanisms in cancer： basis for development and evolution of cancer immune checkpoint inhibitors［J］. Biology （Basel）， 2023，12（2）：218. doi:10.3390/biology12020218 doi: 10.3390/biology12020218
33	CHI X， LUO S， YE P， et al. T-cell exhaustion and stemness in antitumor immunity： characteristics， mechanisms， and implications［J］. Front Immunol， 2023，14：1104771. doi:10.3389/fimmu.2023.1104771 doi: 10.3389/fimmu.2023.1104771
34	CHU X， TIAN W， WANG Z， et al. Co-inhibition of TIGIT and PD-1/PD-L1 in cancer immunotherapy： mechanisms and clinical trials［J］. Mol Cancer， 2023，22（1）：1-31. doi:10.1186/s12943-023-01800-3 doi: 10.1186/s12943-023-01800-3
35	SU Y， YAMAZAKI S， MORISUE R， et al. Tumor-infiltrating T cells concurrently overexpress CD200R with immune checkpoints PD-1， CTLA-4， and TIM-3 in non-small-cell lung cancer［J］. Pathobiology， 2021，88（3）：218-227. doi:10.1159/000511557 doi: 10.1159/000511557
36	武阳，陆翰杰，水会锋. 既往免疫经治的晚期非小细胞肺癌患者接受安罗替尼联合PD⁃1单抗的疗效及安全性［J］. 实用医学杂志， 2023，39（5）：572-578.
37	ITAHASHI K， IRIE T， YUDA J， et al. BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors［J］. Sci Immunol， 2022，7（76）：eabk0957. doi:10.1126/sciimmunol.abk0957 doi: 10.1126/sciimmunol.abk0957
38	ZHANG Z， LIN M， WANG J， et al. Calycosin inhibits breast cancer cell migration and invasion by suppressing EMT via BATF/TGF-β1［J］. Aging （Albany NY）， 2021，13（12）：16009-16023. doi:10.18632/aging.203093 doi: 10.18632/aging.203093
39	ZHANG X， ZHANG C， QIAO M， et al. Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells［J］. Cancer Cell， 2022，40（11）：1407-1422. doi:10.1016/j.ccell.2022.09.013 doi: 10.1016/j.ccell.2022.09.013
40	TREFNY M P， KIRCHHAMMER N， DER MAUR P AUF， et al. Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy［J］. Nat Commun， 2023，14（1）：86. doi:10.1038/s41467-022-35583-w doi: 10.1038/s41467-022-35583-w
41	ZHANG H， LIU S， LI Y， et al. Dysfunction of S100A4⁺ effector memory CD8⁺ T cells aggravates asthma［J］. Eur J Immunol，2022，52（6）：978-993. doi:10.1002/eji.202149572 doi: 10.1002/eji.202149572
42	DIEHL S， KRAHL T， RINALDI L， et al. Inhibition of NFAT specifically in T cells prevents allergic pulmonary inflammation［J］. J Immunol， 2004，172（6）：3597-3603. doi:10.4049/jimmunol.172.6.3597 doi: 10.4049/jimmunol.172.6.3597
43	LIN M， HUANG Z， CHEN Y， et al. Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy［J］. Front Immunol， 2022，13：1038715. doi:10.3389/fimmu.2022.1038715 doi: 10.3389/fimmu.2022.1038715

[1]	Jiang SHAO,Lin LI,Yansong GUO,Chengyuan SUN,Xichao WEN,Kebin ZHENG,Yanfang SHI. Research progress of CD73/NT5E in glioblastoma [J]. The Journal of Practical Medicine, 2024, 40(3): 428-431.
[2]	Zhaochen SUN,Junyan JIANG,Yitian. CHEN. Advancements in CAR⁃T cell research for the treatment of colorectal cancer [J]. The Journal of Practical Medicine, 2024, 40(18): 2640-2646.
[3]	Yawei ZHANG,Hongjin SHI,Shi FU,Jiansong WANG,Haifeng WANG. Research progress in biological role of TIGIT and its application in bladder cancer [J]. The Journal of Practical Medicine, 2024, 40(12): 1762-1766.
[4]	Xizhi WEN,Xiaoshi. ZHANG. Immunotherapy based on neoantigen： A personalized treatment strategy for melanoma [J]. The Journal of Practical Medicine, 2024, 40(10): 1331-1337.
[5]	WU Kaiyi, LÜ Xuedong, HE Haiyan, CHEN Jinliang. . Progress in the application of cryoablation combined with immunotherapy in the treatment of NSCLC [J]. The Journal of Practical Medicine, 2023, 39(8): 1058-1062.
[6]	ZHANG Xijie, LI Xin, ZHOU Wence.. Research progress of combined immunotherapy for metastatic pancreas cancer [J]. The Journal of Practical Medicine, 2023, 39(6): 655-659.
[7]	CHEN Fukun, LV Juan, DENG Zhiyong. Effect of chimeric antigen receptor gene⁃modified T⁃cell immunotherapy for lung cancer：A systematic review [J]. The Journal of Practical Medicine, 2023, 39(5): 538-543.
[8]	WU Yang, LU Hanjie, SHUI Huifeng.. The efficacy and safety of anlotinib plus PD⁃1 blockades in patients with advanced non⁃small cell lung can⁃ cer previously treated with immunotherapy [J]. The Journal of Practical Medicine, 2023, 39(5): 572-578.
[9]	Xianlan ZHANG,Yufei ZHU,Yunyun ZENG,Zhihao HUANG,Wenchang CEN,Shan. SU. Efficacy and safety of chemotherapy plus immunotherapy and recombinant human endostatin in treating advanced non-small cell lung cancer [J]. The Journal of Practical Medicine, 2023, 39(16): 2112-2115.
[10]	TIAN Jing, ZHANG Zhiyong, BAI Tiankai, YAN Bin.. CAR ⁃T therapy for pancreatic cancer：Research progress and prospects [J]. The Journal of Practical Medicine, 2022, 38(4): 516-521.
[11]	XU Lu, HUANG Liyou, WANG Yanhua, WEN Linchun.. Efficacy and safety ofPD ⁃ 1 inhibitor combined with brain radiotherapy for brain metastases in patients with pan⁃negative non⁃small cell lung cancer [J]. The Journal of Practical Medicine, 2022, 38(24): 3100-3105.
[12]	PENG Sijing, LU Jielun, WANG Zicheng, ZENG Xiaozhen, ZOU Yawei.. A progress on immunotherapy for childhood acute lymphoblastic leukemia [J]. The Journal of Practical Medicine, 2022, 38(23): 2903-2907.
[13]	ZHANG Ying, WU Yueling.. Immunotherapy incervical cancer：The advent of precision medicine [J]. The Journal of Practical Medicine, 2022, 38(15): 1856-1859.
[14]	HE Jun, WU Songbai, LYU Ailian, DAI Yao, HUANG Kang, FANG Xiang, LYU Jianlei, LIU Min, ZHANG Quan, PENG Jing. Research on strategy of immunotherapy in elderly sepsis patients with immunosuppression [J]. The Journal of Practical Medicine, 2021, 37(6): 718-721.
[15]	LI Dailong, WANG Yuke, PANG Yaqi, XU Xinhua. Progress of clinical research on immune checkpoint inhibitorsin advanced hepatocellular carcinoma [J]. The Journal of Practical Medicine, 2021, 37(6): 821-826.

Research progress in T cell exhaustion and its relationship with respiratory diseases

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 43

Related Articles 15

Recommended Articles

Metrics

Comments